24/7 Market News Snapshot 25 September, 2025 – AIM ImmunoTech Inc. (NYSE:AIM)

September 25, 2025

DENVER, Colo., 25 September, 2025 (www.247marketnews.com) – (NYSE:AIM) are discussed in this article.
AIM ImmunoTech Inc. is currently witnessing an upward trend in its stock performance, with shares trading at $2.897 during pre-market sessions, marking a notable increase of 5.35% from the previous day’s closing price of $2.750. The trading volume has reached 907.16K, indicative of strong investor interest and potential for further momentum. The recent price movements above crucial resistance levels suggest that AIM might experience increased buying activity. Market indicators are supporting a bullish outlook, and investors are advised to closely monitor for potential breakout patterns while remaining vigilant about broader market trends.

In parallel, AIM has made significant strides in its intellectual property strategy with the issuance of a new patent by the Japan Patent Office. This patent focuses on the innovative application of Ampligen® (Rintatolimod) in conjunction with checkpoint inhibitors, addressing various cancer types. As Japan stands as one of the largest pharmaceutical markets globally and oncology the fastest-growing therapeutic area, this patent positions AIM favorably for international licensing and collaboration opportunities.

This newly obtained patent further strengthens AIM’s existing intellectual property portfolio that includes additional patents in the United States and Europe, and it is valid until December 20, 2039. It broadly encompasses treatment methodologies for several cancer types including pancreatic, breast, and lung cancers, as well as specific dosing regimens designed to maximize the therapeutic synergy of Ampligen alongside checkpoint inhibitors.

Thomas K. Equels, CEO of AIM ImmunoTech, emphasized that securing this patent underscores the company’s dedication to advancing Ampligen’s clinical development. The firm is optimistic about its clinical pipeline, highlighted by collaborations such as a Phase 2 clinical trial with AstraZeneca for metastatic pancreatic cancer and another with Merck Sharp & Dohme LLC for advanced recurrent ovarian cancer, which have shown promising preliminary results. AIM ImmunoTech aims to lead transformative research in cancer therapies to address significant medical needs on a global scale.

Related news for (AIM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.